India Pharma highlights Policy Push and Innovation Driving Sectoral Growth (See 'Corp Brief') IBC - Multi-state co-operative society can invest in another company, including as resolution applicant under IBC, only if target company is either its subsidiary or engaged in same line of business: SC (See 'Legal Desk') Ministry of Labour signs MoUs with Porter and Gigin Technologies (See 'Corp Brief') IBC - Once moratorium is imposed, corporate debtor's pre-CIRP dues cannot be set off against deposit held by creditor: SC (See 'Legal Desk') Medicine is not just profession, it is a commitment to service of humanity: Murmu (See 'Corp Brief') FEMA - SCNs alleging contravention of provisions of FERA merit being quashed, where issued after unjustified delay of 7-10 years, more so where record retention norms generally require preservation for 5-8 years: HC (See 'Legal Desk') Union Minister jighlights Nari Shakti Vandan Adhiniyam as Transformative Reform (See 'Corp Brief') Misc - Once Freezing Authority identifies properties and forms opinion that they are acquired from illicit source of money derived from drug trafficking, burden of proof shifts entirely onto affected persons to controvert allegations: SAFEMA (See 'Legal Desk') Bizu Festival Celebrations highlight Cultural Pride and Policy Dialogue on Tribal Development (See 'Corp Brief') India, Kuwait emphasize Dialogue Over Conflict to Secure Energy and Trade Supplies (See 'Corp Brief') Misc - There is no right in borrower to personal hearing by banks before classifying their account as fraud account: SC (See 'Legal Desk') Manohar Lal holds Key Engagements on Infrastructure and Development Cooperation (See 'Corp Brief') CARI Bengaluru gets ISO 15189:2022 Accreditation in Biochemistry (See 'Corp Brief') NI Act - At stage of issuance of process, statutory presumption u/s 139 of NI Act cannot be dislodged in summary manner merely by contending that cheque issued was not for legally enforceable debt: SC (See 'Legal Desk') Barabanki to Bahraich Highway to become Key Cross-Border Trade Lifeline (See 'Corp Brief') Advanced Agriculture fest kicks off in Raisen in MP (See 'Corp Brief') PMLA - Sec 2(1)(u) permits attachment of any property of equivalent value, including properties acquired prior to commission of scheduled offence, which are untraceable: SAFEMA (See 'Legal Desk') NTWB welcomes Jan Vishwas Amendments (See 'Corp Brief') IPR - Controller of Patent would decide whether differences, viewed in knowledge of alleged invention, constitute steps which would have been obvious to ordinary person skilled in art and rule out hindsight approach: HC (See 'Legal Desk') Anand Kumar Pal joins MoF as Chief Cost Adviser (See 'Corp Brief') IPR - Generic disclosure does not, by itself, defeat novelty of specific disclosure; Prior art that teaches away from claimed invention cannot serve as foundation for anticipation: HC (See 'Legal Desk') India-GCC reaffirms commitment to Regional Stability (See 'Corp Brief') IPR - Prior user of trademark has superior rights over subsequent user who holds registration for same or similar mark: HC (See 'Legal Desk') India-Bahrain stresses stability, Supply Chain Resilience and Stronger Economic Ties (See 'Corp Brief') Company Law - Sourcing pre-condition deposit unlawfully from corporate funds in direct violation of Sec 185, or executing settlement agreements without effectuating actual refunds or delivering legally valid & habitable possession, is illegal: SC (See 'Legal Desk') Supreme Court Clears Path For Single Insolvency Proceedings Against Linked Group Companies (See CORP EINSICHT)

Print

India Pharma highlights Policy Push and Innovation Driving Sectoral Growth

Published: Apr 14, 2026

By TIOLCorplaws News Service

NEW DELHI, APR 14, 2026: THE 9th edition of India Pharma 2026, the flagship event of the Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers, Government of India, commenced yesterday in New Delhi. Organized in collaboration with the Federation of Indian Chambers of Commerce and Industry (FICCI) and the Indian Pharmaceutical Alliance (IPA), the two-day conference brings together key stakeholders from across the global pharmaceutical and healthcare ecosystem, with a strong focus on innovation, self-reliance, and global leadership.

Addressing the inaugural session virtually Union Minister of Health & Family Welfare and Chemicals & Fertilizers, J.P. Nadda, emphasized that the platform reflects both the strength and growing global relevance of India's pharmaceutical sector. He noted that while India has long been recognized as the "pharmacy of the world" due to its leadership in affordable generic medicines, the global landscape is now rapidly shifting towards biologics, biosimilars, and specialty medicines. "In this evolving environment, India is well positioned not only to adapt but to emerge as a global leader," he stated. Reaffirming the Government's commitment to fostering innovation and strengthening research capabilities, he highlighted the recently launched Biopharma Shakti Initiative with an outlay of Rs.10,000 crore, aimed at advancing capabilities in biopharmaceutical innovation under the leadership of Prime Minister Narendra Modi.

He further underscored complementary initiatives such as the PRIP scheme for promoting research in pharmaceuticals and medical technology, which seek to deepen industry-academia collaboration and accelerate the development of innovative therapies. Strengthening domestic manufacturing remains a key priority, supported by schemes like the Production Linked Incentive (PLI) schemes and the development of bulk drug parks to enhance self-reliance and resilient supply chains. He also reiterated the Government's commitment to affordable healthcare through initiatives such as the Pradhan Mantri Bharatiya Jan Aushadhi Pariyojana, which continues to expand access to quality medicines at affordable prices across the country.

He added that India Pharma 2026 provides a vital platform to foster dialogue, partnerships, and a forward-looking roadmap for the sector.

Minister of State for Health & Family Welfare and Chemicals & Fertilizers, Anupriya Patel, highlighted that India is undergoing a significant transition from being a global generics leader to an emerging biopharma innovation hub. She noted that India currently contributes nearly 20% of global generic medicines and meets around 70% of global vaccine demand, underscoring the country's robust manufacturing capabilities.

Emphasizing future opportunities, she stated that the global demand for biologics and biosimilars is expanding rapidly, with the biosimilars market projected to reach USD75 billion by 2030. She further pointed out that innovative drugs account for nearly 87% of the global pharmaceutical market value, underlining the need for India to intensify its focus on innovation-driven segments.

Patel also outlined the integration of artificial intelligence in drug discovery and development. She emphasized the importance of strengthening human capital through premier institutions such as NIPERs and IITs to support advanced research and innovation.

Manoj Joshi, Secretary, Department of Pharmaceuticals, stressed the need to accelerate innovation timelines, strengthen startup ecosystems, and build robust infrastructure for clinical trials and advanced research. He highlighted the importance of enhanced funding mechanisms, closer industry-government collaboration, and development of skilled talent.

Punya Salila Srivastava, Secretary, Ministry of Health & Family Welfare, reiterated the Government's commitment to strengthening the regulatory ecosystem and enabling innovation. She noted that several measures have been undertaken to streamline approval processes and improve the ease of doing research, with the aim of transforming India from the "pharmacy of the world" to an "innovator for the world."

Arjun Juneja, Chair, FICCI Pharma Committee and COO, Mankind Pharma, highlighted India's strong pharmaceutical base, noting the presence of over 3,000 companies and more than 10,500 manufacturing facilities, including the highest number of USFDA-compliant plants outside the United States. He emphasized the need for deeper collaboration between Indian and global players to drive innovation-led growth.

Achin Gupta, Co-Chair, FICCI Pharma Committee and MD & Global CEO, Cipla Ltd, delivered the vote of thanks.

The two-day conference and exhibition will feature deliberations on policy frameworks for innovation, artificial intelligence in drug discovery, next-generation technologies, and strategies to enhance India's global competitiveness in life sciences. The event is expected to play a pivotal role in shaping the future roadmap of the pharmaceutical sector and reinforcing India's position as a global healthcare leader.

 

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.